Q-omics provides the consensus-scored TPMT profile across patient tissues and cancer cell-line models. TPMT expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, TPMT is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TPMT RNA expression shows 19,768 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, HNSC, and UVM as cancer lineages where TPMT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPMT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPMT survival associations across molecular data types. TPMT RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPMT RNA expression–survival associations across cancer types. High TPMT expression shows unfavorable associations in KICH, ACC and UVM, but favorable associations in OV, KIRC and KIRP. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for TPMT RNA expression.
This table summarizes TPMT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TPMT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPMT shows lower tumor expression in KICH, THCA and KIRP and higher tumor expression in HNSC, STAD and LUAD. The HNSC box plot shows higher TPMT RNA expression in tumor versus normal tissue (log2 FC = +0.965, t-test p < 0.001).
This table shows molecular features associated with TPMT in patient tissues and cancer cell lines. In patient samples, TPMT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TPMT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
